Research
Hormonal
Long-term use of inhaled corticosteroids (ICS) with standard-sized particles increases the risk of developing OSA due to pharyngeal muscle atrophy and neck fat redistribution, whereas extra-fine particles do not show this increased risk.
If you use standard inhaled corticosteroids and have sleep apnea, ask your doctor about switching to extra-fine particle formulations. These may reduce the risk of worsening sleep apnea while still controlling your asthma, as they deposit deeper in the lungs rather than the throat.
ModerateQualifiesMEDIUM confidence
Previous studies in canine models have indicated that corticosteroids... paradoxically lead to adverse effects on pharyngeal muscles. This includes muscle fiber atrophy and redistribution of central neck fat, ultimately promoting OSA... inhalers containing standard-sized particles increased the risk of OSA. Larger ICS particles tend to deposit preferentially in the upper airway and posterior pharynx, causing local adverse effects
Why this rating
Based on canine models, surveys, and limited prospective studies; requires more human data.
Source
The interconnection between Obesity and Asthma-Obstructive Sleep Apnea Overlap: A Comprehensive Review
Paula Vasilache Antohi et al. · Pneumologia · 2023
DOI 10.2478/pneum-2024-0018
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity (BMI ≥ 25 kg/m²) is a critical, modifiable independent risk factor that drives the bidirectional overlap between asthma and obstructive sleep apnea (OSA) through mechanisms including altered lung mechanics, airway hyperresponsiveness, and adipokine production.Good
- GLP-1 agonists (e.g., tirzepatide) and metformin show promise in improving asthma outcomes in obese patients by enhancing insulin sensitivity and reducing airway inflammation, though specific FDA approvals for obesity-associated asthma are lacking.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →